At a Glance
- Companies: Alnylam Pharmaceuticals and Inceptive Nucleics
- Upfront value: $30 million, including cash and equity
- Total deal value: Up to $2 billion
- Focus area: siRNA design for RNA interference therapeutics
- Next steps: Use AI to prioritise better RNAi candidates
What happened?
Alnylam has entered into a strategic collaboration with Inceptive Nucleics to speed up discovery and development of next-generation RNAi therapies. The agreement is designed to improve siRNA design by combining Alnylam’s RNAi expertise with Inceptive’s generative AI models.
Why does it matter?
This is Alnylam’s first discovery-focused AI deal, and it could help the company move faster in a field where sequence design and chemical modification choices strongly affect potency and efficacy. Better model-guided selection could reduce experimental burden and improve the odds of finding strong therapeutic candidates.
Who’s behind it?
Alnylam is the RNAi pioneer with more than 20 years of proprietary siRNA data and several approved drugs. Inceptive is an AI company that builds foundation models for biology and says its systems generalise well to sequence-based medicines.
How was it achieved?
The collaboration will use Inceptive’s generative models to model target mRNAs, explore sequence space and test chemical modifications that may improve siRNA performance. The companies said early joint work showed the models could quickly generate useful biological insights from relatively small datasets.
What’s next?
Alnylam plans to use the platform to prioritise the most promising siRNA molecules and improve experimental productivity as part of its Alnylam 2030 strategy. Inceptive could also receive milestone payments tied to preclinical, regulatory and commercial progress.